Publications 2020

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM (2019)
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
J Natl Cancer Inst, 111 (11), 1202-1215
DOI 10.1093/jnci/djz051, PubMed 30990221

Publications 2018

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530

Publications 2017

Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Samuel N, Id Said B, Guha T, Novokmet A, Li W, Silwal-Pandit L, Børrsen-Dale AL, Langerød A, Hudson TJ, Malkin D (2017)
Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk
Hum Mutat, 38 (3), 265-268
DOI 10.1002/humu.23154, PubMed 27957778

Silwal-Pandit L, Langerød A, Børresen-Dale AL (2017)
TP53 Mutations in Breast and Ovarian Cancer
Cold Spring Harb Perspect Med, 7 (1)
DOI 10.1101/cshperspect.a026252, PubMed 27815305

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Publications 2016

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Publications 2015

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C (2015)
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
DOI 10.1101/gad.263202.115, PubMed 26080815

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
PLoS One, 10 (10), e0139965
DOI 10.1371/journal.pone.0139965, PubMed 26460974

Publications 2014

Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C, Balmain A, Børresen-Dale AL, Kristensen V (2014)
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53
Mol Cancer Res, 13 (3), 493-501
DOI 10.1158/1541-7786.MCR-14-0387, PubMed 25351767

Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Langerød A (2014)
TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance
Clin Cancer Res, 20 (13), 3569-80
DOI 10.1158/1078-0432.CCR-13-2943, PubMed 24803582